Dr. Kimberley S. Mak
Claim this profileBoston Medical Center
Studies Lung Cancer
Studies Cancer
5 reported clinical trials
16 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage I
2Cancer
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Kimberley S. Mak is currently running
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
MRI Monitoring vs. Preventive Brain Radiation
for Small Cell Lung Cancer
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Recruiting2 awards Phase 322 criteria
More about Kimberley S. Mak
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Kimberley S. Mak has experience with
- SAbR
- Lung Surgery
- Docetaxel
- Gemcitabine
- Erlotinib Hydrochloride
- Local Consolidation Therapy
Breakdown of trials Kimberley S. Mak has run
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kimberley S. Mak specialize in?
Kimberley S. Mak focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage I.
Is Kimberley S. Mak currently recruiting for clinical trials?
Yes, Kimberley S. Mak is currently recruiting for 4 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Kimberley S. Mak has studied deeply?
Yes, Kimberley S. Mak has studied treatments such as SAbR, Lung Surgery, Docetaxel.
What is the best way to schedule an appointment with Kimberley S. Mak?
Apply for one of the trials that Kimberley S. Mak is conducting.
What is the office address of Kimberley S. Mak?
The office of Kimberley S. Mak is located at: Boston Medical Center, Boston, Massachusetts 02118 United States. This is the address for their practice at the Boston Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.